Evaluation of PD-L1 expression in undifferentiated pleomorphic sarcomas, liposarcomas and chondrosarcomas
Y Zhang, Y Chen, A Papakonstantinou, P Tsagkozis… - Biomolecules, 2022 - mdpi.com
Immune checkpoint inhibitors (ICIs) such as PD1/PD-L1 blockers are an established
treatment for many solid cancers. There are currently no approved ICIs for sarcomas, but …
treatment for many solid cancers. There are currently no approved ICIs for sarcomas, but …
Sensitization with an allogeneic MHC class I molecule induces anti-tumor immunity in the absence of PD-1 in mice
KA Paramitasari, Y Ishida - bioRxiv, 2023 - biorxiv.org
To investigate the effect of a major histocompatibility complex class I (MHC-I)
overexpression to augment immune sensitivity against tumors, we have generated the …
overexpression to augment immune sensitivity against tumors, we have generated the …
[图书][B] Morphologic and genetic features of sarcomas: improving diagnosis and exploring biomarkers
Y Zhang - 2022 - search.proquest.com
Sarcomas are malignant tumors of soft tissue and bone origin. They are a family of rare but
diverse neoplasms which pose clinical challenges due to their heterogeneous properties. In …
diverse neoplasms which pose clinical challenges due to their heterogeneous properties. In …
[PDF][PDF] Sensitization with allogeneic MHC class I molecule H-2Kd induces anti-tumor immunity in the context of PD-1 blockade
AP Komang - 2022 - naist.repo.nii.ac.jp
Immune response to cancer is induced upon recognition of antigen-bound major
histocompatibility complex class I (MHC-I) by the T-cell receptor (TCR). Following the killing …
histocompatibility complex class I (MHC-I) by the T-cell receptor (TCR). Following the killing …